Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial

Mugglehead
By Theo MarchettiSep 23, 2026, 1:09 pm78 pts
Health Canada's previously authorized Phase 2 depression trial for up to 200 people gained a quality-released 5 mg psilocybin batch on Sept. 23. Optimi Health Corp. (CNSX: OPTI) (NASDAQ: OPTH) shares traded at US$4.98 on Nasdaq at 11:40 a.m. EDT on Sept. 23. Optimi said the capsules will supply its planned…

Read Article Share
Share Article
- email
- x.com
- facebook
- pocket
- reddit
- tumblr
- linkedin
- pinterest

Trending Today on NewsBudz

Optimi Health releases 5 mg psilocybin batch for Canadian Phase 2 trial 78

Study Finds THC-CBD Marijuana Extracts Linked to Reduced Pain and Opioid Use in Women With Endometriosis 77

Curaleaf enters FTSE Canada All Cap Index in September review 76

Oregon Officials Drop Plans to Increase Psilocybin Licensing Fees 67

Federal Watchdog Finds Gaps in DEA and FDA Drug-Scheduling Policies Amid Marijuana Rescheduling Process 63

CBD-Chemotherapy Combination Shows Enhanced Activity Against Human Ovarian Cancer Cells 58

Washington Cannabis Regulators Seek Nearly $12 Million for New Marijuana Traceability System 51

About NewsBudz

NewsBudz is your go-to app for daily cannabis news, covering everything from medical marijuana breakthroughs to recreational cannabis trends and legalization updates.

Our platform aggregates content from over 30 top-tier cannabis news outlets to deliver a curated stream of the latest headlines, insights, and developments across the marijuana and hemp industries.

Whether you're interested in policy reform, health research, cannabis business, CBD, delta 9 products or lifestyle stories, NewsBudz keeps you informed and connected. Accessible on the web and mobile, NewsBudz makes it easy to explore, read, and share cannabis news anytime, anywhere.